Your shopping cart is currently empty

NU6102 is a selective and potent ATP-competitive CDK2 inhibitor with antitumor activity against CDK1/cyclinB, CDK2/cyclinA3, CDK1/CDK2, CDK4, DYRK1A , PDK1, and ROCKII, and it can be used to study rectal cancer.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $38 | In Stock | In Stock | |
| 5 mg | $89 | In Stock | In Stock | |
| 10 mg | $135 | In Stock | In Stock | |
| 25 mg | $245 | In Stock | In Stock | |
| 50 mg | $366 | In Stock | In Stock | |
| 100 mg | $543 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $93 | In Stock | In Stock |
| Description | NU6102 is a selective and potent ATP-competitive CDK2 inhibitor with antitumor activity against CDK1/cyclinB, CDK2/cyclinA3, CDK1/CDK2, CDK4, DYRK1A , PDK1, and ROCKII, and it can be used to study rectal cancer. |
| Targets&IC50 | CDK1-CyclinB:9.5 nM, DYRK1A:0.9 μM, PDK1:0.8 μM, CDK2-CyclinA3:5.4 nM, CDK4:1.6 μM |
| In vitro | Treatment with NU6102 (0-30 μM; 1-24 hours) induces G2 arrest, inhibition of Rb phosphorylation, and cytotoxicity (LC50 2.6 μM for a 24-hour exposure) in SKUT-1B cells[3]. NU6102 inhibits cell growth and causes cell cycle phase arrest in human breast cancer cell lines, displaying G2/M arrest in asynchronously growing cell lines and G1/S arrest in cells released from serum starvation, and in Xenopus nuclei in a time-dependent manner[3]. Moreover, NU6102 selectively inhibits the growth of CDK2 WT (wild type) compared to KO MEFs (knockout mouse embryo fibroblasts) with a GI50 of 14 μM versus >30 μM[3]. |
| In vivo | The pharmacokinetics of NU6102 are determined in Balb/C mice following i.v. and i.p. administration. Due to the limited solubility of NU6102, the maximum administrable dose is 1 mg/kg i.v. and 10 mg/kg i.p. NU6102 is liberated following either i.p. or i.v. administration of NU6301. After i.v. administration, peak plasma levels of 12 μM NU6102 are observed 5 minutes post-administration, while the peak concentration achieved with the maximum administrable dose of NU6102 i.v. is 0.92 μM. The plasma half-life of NU6102 liberated following NU6301 administration is 42 minutes after i.p. and 10 minutes after i.v. administration[3]. |
| Synonyms | NU-6102, NU 6102 |
| Molecular Weight | 402.47 |
| Formula | C18H22N6O3S |
| Cas No. | 444722-95-6 |
| Smiles | NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (99.39 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.97 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.